At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled / 26 target
Drug / intervention
Nivolumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Adjuvant Nivolumab in Patients With Resected Stage IIB/IIC Melanoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted Jan 19, 2018·Updated Jun 16, 2026
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Melanoma (Skin). Completed, enrolled 26 participants across 4 sites.
Signals
Enrollment appears stalled
Detailed Summary
This phase II trial studies how well nivolumab works in treating patients with stage IIB-IIC melanoma that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma (Skin)
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJan 2018
First PostedJan 2018
Primary CompletionDec 2025
TodayJul 2026
First PostedJan 19, 2018
Enrollment StartJan 17, 2018
Primary CompletionDec 15, 2025
TodayJul 2, 2026
Enrollment to primary: 7.9 yearsPosted 8.5 years ago
Arms & Interventions
Treatment (nivolumab)experimental
Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Biological: Nivolumab
Interventions
Nivolumabbiological
Given IV